title: Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium.
abstract: OBJECTIVE
  To evaluate changes in bone density in women receiving enoxaparin sodium during pregnancy.
  
  
  METHODS
  Bone density in the proximal femur was serially measured in 16 women receiving enoxaparin sodium (40 mg daily) during pregnancy. Baseline measurements were taken within 2 weeks of starting therapy and then at 6-8 weeks postpartum and 6 months postpartum.
  
  
  RESULTS
  Patients received enoxaparin sodium for a mean duration of 25 weeks (range, 19-32 weeks). There was no significant change in mean bone density measurement from baseline measurements to the conclusion of therapy at 6 weeks postpartum and no patient experienced a decrease in bone mass of >10% at 6 weeks postpartum. By 6 months postpartum, there was a significant mean decrease in bone density (P = 0.02) and two of the 14 patients evaluated (14%) experienced an overall bone loss of >10%.
  
  
  CONCLUSIONS
  The prolonged used of enoxaparin sodium may not cause significant bone loss during pregnancy.
authors.affiliation: Department of Obstetrics and Gynecology, Evanston Hospital, Northwestern University Medical School, Illinois 60201, USA. h-casele@nwu.edu
authors.forename: H L
authors.initials: HL
authors.lastname: Casele
authors.forename: S A
authors.initials: SA
authors.lastname: Laifer
mesh_terms: D000328:Adult; D015519:Bone Density; D017984:Enoxaparin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D010024:Osteoporosis / Q000139:chemically induced; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000517:prevention & control; D011446:Prospective Studies; D013927:Thrombosis / Q000517:prevention & control; D013997:Time Factors
chemical_list: D017984:Enoxaparin